(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -20.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Cytomx Therapeutics's revenue in 2025 is $138,103,000.On average, 5 Wall Street analysts forecast CTMX's revenue for 2025 to be $8,496,675,826, with the lowest CTMX revenue forecast at $5,959,431,742, and the highest CTMX revenue forecast at $12,455,532,740. On average, 3 Wall Street analysts forecast CTMX's revenue for 2026 to be $5,250,547,724, with the lowest CTMX revenue forecast at $1,197,493,341, and the highest CTMX revenue forecast at $8,130,138,734.
In 2027, CTMX is forecast to generate $6,426,654,394 in revenue, with the lowest revenue forecast at $4,005,074,550 and the highest revenue forecast at $8,130,138,734.